{"id":510832,"date":"2021-07-08T08:04:10","date_gmt":"2021-07-08T12:04:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/"},"modified":"2021-07-08T08:04:10","modified_gmt":"2021-07-08T12:04:10","slug":"aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/","title":{"rendered":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines"},"content":{"rendered":"<h2>\nAIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories.<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">AUSTIN, Texas, July  08, 2021  (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH) today announced its OVA1<sup>\u00ae<\/sup> risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health\u2019s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation\u2019s largest health care organizations. AIM\u2019s mission is to promote appropriate, safe, and affordable health care. As one of the nation\u2019s leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.<\/p>\n<p>The OVA1<sup>\u00ae<\/sup> test is now included in AIM\u2019s guidelines for the preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation. The guidelines also include OVA1<sup>\u00ae<\/sup> for the determination of the required surgical approach, operator expertise and level of care for an adnexal mass.<\/p>\n<p>Recent positive coverage additions for OVA1<sup>\u00ae<\/sup>, such as New York State Medicaid, coupled with peer-reviewed publications documenting OVA1<sup>\u00ae<\/sup>\u2019s superior clinical performance as compared to CA125, especially among Black women, has resulted in a dramatic increase in the number of women who have access to the OVA1<sup>\u00ae<\/sup> technology. Aspira Labs, Inc., a subsidiary of Aspira Women\u2019s Health, is the only U.S. provider for Aspira\u2019s proprietary OVA1<sup>\u00ae<\/sup> test, an FDA-cleared, ACOG recommended, and Medicare covered ovarian cancer risk assessment tool for women with a pelvic mass.<\/p>\n<p>\u201cWe are excited to provide access to OVA1plus<sup>TM<\/sup>, to such a large segment of the population,\u201d said Valerie Palmieri, President and CEO of Aspira Women\u2019s Health Inc. \u201cThis guideline from an organization with a robust technology assessment process expands our ability to truly change the standard of care and helps advance our commitment to making OVA1<sup>\u00ae<\/sup> accessible to ALL women.\u201d<\/p>\n<p>\n        <strong>About Aspira Women\u2019s Health Inc.<\/strong><br \/>\n        <br \/>Aspira Women\u2019s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women\u2019s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women\u2019s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus<sup>TM<\/sup> combines our FDA-cleared products, OVA1<sup>\u00ae<\/sup> and OVERA<sup>\u00ae<\/sup>, to detect risk of ovarian malignancy in women with adnexal masses. [Aspira GenetiX<sup>TM<\/sup>] testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women\u2019s Health is delivering a portfolio of pelvic mass products over a patient\u2019s lifetime with our cutting-edge research. The next generation of products in development are [OVASight<sup>TM<\/sup> and EndoCheck<sup>TM<\/sup>]. Visit our website for more information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=faZDSJbYaasNpygxWjlL2v0EIEfu4YXCm-0-17ISbkjuVeb3Px5drGcjJ9Vgg7n6s2qgvSx6yEmdERkdIXoK5w==\" rel=\"nofollow noopener\" target=\"_blank\">www.aspirawh.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashley R. Robinson <br \/>LifeSci Advisors, LLC <br \/>Tel 617-430-7577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e10TIw9npwnFnOjGMmuelD-aksHeyf-gXtFQOvBAkbgBwRBjJruGF3YyxO7D1jWqmJMtbhnUvvchgbwDn2ICRlh_izyXsVYgklKVo8mpRbM=\" rel=\"nofollow noopener\" target=\"_blank\">Arr@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/cfd0f053-bdf1-424a-a019-4ddec761d2ab\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH) today announced its OVA1\u00ae risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health\u2019s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation\u2019s largest health care organizations. AIM\u2019s mission is to promote appropriate, safe, and affordable health care. As one of the nation\u2019s leading specialty benefits management firms, AIM helps &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510832","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH) today announced its OVA1\u00ae risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health\u2019s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation\u2019s largest health care organizations. AIM\u2019s mission is to promote appropriate, safe, and affordable health care. As one of the nation\u2019s leading specialty benefits management firms, AIM helps &hellip; Continue reading &quot;Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-08T12:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines\",\"datePublished\":\"2021-07-08T12:04:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/\"},\"wordCount\":547,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/\",\"name\":\"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\",\"datePublished\":\"2021-07-08T12:04:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/","og_locale":"en_US","og_type":"article","og_title":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk","og_description":"AIM is a wholly owned subsidiary of Anthem, Inc., serving more than 50 million members across 50 states, D.C., and US territories. AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) &#8212; Aspira Women\u2019s Health Inc. (Nasdaq: AWH) today announced its OVA1\u00ae risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health\u2019s Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nation\u2019s largest health care organizations. AIM\u2019s mission is to promote appropriate, safe, and affordable health care. As one of the nation\u2019s leading specialty benefits management firms, AIM helps &hellip; Continue reading \"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-08T12:04:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines","datePublished":"2021-07-08T12:04:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/"},"wordCount":547,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/","name":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==","datePublished":"2021-07-08T12:04:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzM4MCM0Mjg4NjAzIzUwMDA0NTYzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-inc-announces-coverage-for-ova1-in-the-aim-specialty-health-laboratory-medicine-clinical-guidelines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aspira Women\u2019s Health Inc. Announces\u00a0Coverage for OVA1\u00ae in the AIM Specialty Health\u00a0Laboratory Medicine Clinical Guidelines"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510832"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510832\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}